J Frontier Co., Ltd. (JP:2934)
:2934
Want to see JP:2934 full AI Analyst Report?
Top Page
J Frontier Co., Ltd.
(2934)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥1,665.00
▲(25.57% Upside)
Action:Reiterated
Date:12/03/25
The overall stock score is primarily impacted by the company's financial performance challenges and bearish technical indicators. The high P/E ratio suggests overvaluation, further contributing to a low score. The lack of earnings call data and corporate events means these factors did not influence the score.
Positive Factors
Free cash flow improvement
Reported improvement in free cash flow growth provides a durable source of internal funding that can support capex, working capital and debt repayment over the medium term. Sustained FCF improvement increases financial flexibility even if operating cash flow remains uneven.
Negative Factors
Sharp revenue decline
A roughly 69% year-over-year revenue contraction is a material structural weakness that impairs scale economics, weakens pricing leverage and impedes reinvestment. Restoring top-line growth is essential for sustainable margins and long-term recovery of profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow improvement
Reported improvement in free cash flow growth provides a durable source of internal funding that can support capex, working capital and debt repayment over the medium term. Sustained FCF improvement increases financial flexibility even if operating cash flow remains uneven.
Read all positive factors
J Frontier Co., Ltd. (2934) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.25B
Dividend YieldN/A
Average Volume (3M)40.58K
Price to Earnings (P/E)6.4
Beta (1Y)0.94
Revenue Growth-0.69%
EPS GrowthN/A
CountryJP
Employees315
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)17.79
Shares Outstanding5,333,465
10 Day Avg. Volume58,880
30 Day Avg. Volume40,583
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)5.74
Price to Sales (P/S)0.38
P/FCF Ratio18.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
J Frontier Co., Ltd. Business Overview & Revenue Model
Company Description
J Frontier Co.,Ltd. engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan. It is involved in various activities, including online medical care, medication guidance, as well as operates drug delivery platfo...
How the Company Makes Money
null...
J Frontier Co., Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
55
Neutral
| Breakdown | May 2024 | May 2023 | May 2022 | May 2022 | May 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.50B | 17.71B | 16.84B | 11.88B | 8.49B |
| Gross Profit | 9.57B | 8.33B | 7.12B | 5.40B | 6.63B |
| EBITDA | 914.54M | -1.22B | -1.54B | 760.66M | 706.10M |
| Net Income | 87.57M | -2.09B | -1.90B | 400.52M | 424.93M |
Balance Sheet | |||||
| Total Assets | 9.17B | 11.41B | 7.25B | 6.10B | 2.59B |
| Cash, Cash Equivalents and Short-Term Investments | 2.17B | 1.81B | 1.65B | 2.96B | 1.64B |
| Total Debt | 4.34B | 5.16B | 2.14B | 544.39M | 75.21M |
| Total Liabilities | 7.16B | 9.53B | 4.54B | 1.94B | 1.33B |
| Stockholders Equity | 1.41B | 1.14B | 2.48B | 4.14B | 1.27B |
Cash Flow | |||||
| Free Cash Flow | 447.19M | -1.54B | -1.94B | -377.40M | 823.99M |
| Operating Cash Flow | 509.01M | -1.44B | -1.83B | -366.94M | 830.91M |
| Investing Cash Flow | 470.79M | -1.79B | -1.13B | -860.09M | -7.99M |
| Financing Cash Flow | -623.13M | 3.39B | 1.45B | 2.56B | -93.65M |
J Frontier Co., Ltd. Technical Analysis
Positive
1326.00
Price Trends
1355.06
Positive
1378.77
Positive
1576.78
Positive
Market Momentum
77.54
Negative
68.42
Neutral
61.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2934, the sentiment is Positive. The current price of 1326 is below the 20-day moving average (MA) of 1436.80, below the 50-day MA of 1355.06, and below the 200-day MA of 1576.78, indicating a bullish trend. The MACD of 77.54 indicates Negative momentum. The RSI at 68.42 is Neutral, neither overbought nor oversold. The STOCH value of 61.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2934.
J Frontier Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ¥175.90B | 31.32 | ― | 0.43% | 20.95% | 13.39% | |
52 Neutral | ¥7.36B | 35.90 | ― | ― | 17.70% | -27.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥71.00B | -232.45 | 5.76% | ― | 23.30% | -56.05% | |
44 Neutral | ¥2.41B | -4.65 | ― | ― | 18.86% | 38.80% | |
42 Neutral | ¥9.25B | 6.41 | ― | ― | -0.69% | ― |
* Healthcare Sector Average
JP:2934
J Frontier Co., Ltd.
1,734.00
90.00
5.47%
JP:4480
Medley
2,169.00
-1,031.00
-32.22%
JP:4438
Welby Inc.
286.00
-63.00
-18.05%
JP:4483
JMDC Inc.
2,688.00
-438.79
-14.03%
JP:9218
Mental Health Technologies Co. Ltd.
700.00
-16.71
-2.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.